Nov 3, 8:07 AM ET
Amneal reported third-quarter 2026 net revenue of $863 million, up 10%, and Adjusted EBITDA of $207 million, up 30%, but swung to a GAAP net loss of $22 million from net income a year earlier, driven by acquisition and integration costs and a higher tax provision. The company raised its full-year 2026 revenue, Adjusted EBITDA and adjusted EPS guidance, while lowering its operating cash flow guidance, which it attributed to higher inventory levels.
- Q3 2026 net revenue was $863 million, up from $785 million in Q3 2025; Adjusted EBITDA was $207 million, up 30%.
- GAAP net loss attributable to Amneal was $22 million, or $(0.06) per diluted share, compared with net income of $2 million a year earlier; adjusted diluted EPS was $0.26, up 53% from $0.17.
- Full-year 2026 net revenue guidance rose to $3.15 billion to $3.25 billion from $3.10 billion to $3.20 billion; Adjusted EBITDA guidance rose to $800 million to $815 million from $750 million to $780 million.
- Operating cash flow guidance was lowered to $325 million to $375 million from $350 million to $400 million, reflecting working capital, including higher inventory levels.
Read the filing on SEC.gov ↗
Aug 10, 4:05 PM ET
Amneal Pharmaceuticals completed its acquisition of Kashiv BioSciences on August 10, 2026, paying in part with 28,942,098 newly issued Class A shares. The company also borrowed a $350 million incremental term loan, with proceeds used as part of the purchase consideration, and says the deal adds a long-term biosimilars growth pillar. The filing does not disclose financial results or the total purchase price, so the effect on earnings and the share count is not yet quantified.
- Acquisition of Kashiv BioSciences, LLC closed on August 10, 2026, under a Membership Interest Purchase Agreement dated April 21, 2026
- Amneal issued 28,942,098 shares of Class A Common Stock to the sellers in a private placement exempt from registration
- $350 million incremental term loan made by Bank of America, N.A. under Amendment No. 4 to the Term Loan Credit Agreement with JPMorgan Chase Bank, N.A. as agent
- Amneal plans to file Kashiv financial statements and pro forma information by amendment, and to register the shares for resale on Form S-3
Read the filing on SEC.gov ↗
Aug 3, 4:28 PM ET
Amneal Pharmaceuticals LLC, a subsidiary of Amneal Pharmaceuticals, Inc., entered into Amendment No. 3 to its Term Loan Credit Agreement on August 3, 2026, reducing the interest rate margin on its term loans by 50 basis points. The company estimates annualized cash interest savings of approximately $12 million compared with the prior agreement, based on amounts outstanding before the amendment.
- Existing term loans converted into new term loans with an aggregate principal amount of $2.039 billion
- A new $45.2 million term loan was incurred, with proceeds used to prepay remaining existing term loans at par
- Margin reduced to 1.50% for base rate loans and 2.50% for SOFR-based loans; stated maturity remains August 1, 2032
- Estimated annualized cash interest savings of approximately $12 million; no prepayment premium on a repricing after February 3, 2027
Read the filing on SEC.gov ↗
Jul 30, 6:15 AM ET
Amneal reported second-quarter 2026 net revenue of $796 million, up 10% from $725 million a year earlier, and GAAP net income attributable to the company of $58 million, up from $22 million. The company raised its full-year 2026 guidance for net revenue, adjusted EBITDA and adjusted diluted EPS, and said a July term loan repricing is expected to cut annual cash interest by about $12 million.
- Q2 2026 net revenue was $796 million, up 10%; Specialty rose 17%, Affordable Medicines rose 13%, and AvKARE fell 4%.
- GAAP diluted EPS was $0.18 versus $0.07 a year earlier; adjusted diluted EPS was $0.30 versus $0.25, up 20%.
- Adjusted EBITDA was $206 million, up 12% from the second quarter of 2025.
- 2026 guidance raised: net revenue $3.10 billion to $3.20 billion (prior $3.05 billion to $3.15 billion); adjusted diluted EPS $0.96 to $1.06 (prior $0.95 to $1.05).
Read the filing on SEC.gov ↗
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.